DE60212836D1 - Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten - Google Patents
Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheitenInfo
- Publication number
- DE60212836D1 DE60212836D1 DE60212836T DE60212836T DE60212836D1 DE 60212836 D1 DE60212836 D1 DE 60212836D1 DE 60212836 T DE60212836 T DE 60212836T DE 60212836 T DE60212836 T DE 60212836T DE 60212836 D1 DE60212836 D1 DE 60212836D1
- Authority
- DE
- Germany
- Prior art keywords
- pyridylpyrimidine
- derivatives
- prion
- pyridylpyrimidine derivatives
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- YJVKLLJCUMQBHN-UHFFFAOYSA-N 2-pyridin-2-ylpyrimidine Chemical class N1=CC=CC=C1C1=NC=CC=N1 YJVKLLJCUMQBHN-UHFFFAOYSA-N 0.000 title abstract 6
- 208000024777 Prion disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- 102000029797 Prion Human genes 0.000 abstract 3
- 108091000054 Prion Proteins 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 abstract 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 abstract 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000004715 cellular signal transduction Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111858 | 2001-05-16 | ||
| EP01111858 | 2001-05-16 | ||
| US29352801P | 2001-05-29 | 2001-05-29 | |
| US293528P | 2001-05-29 | ||
| EP01117113 | 2001-07-13 | ||
| EP01117113 | 2001-07-13 | ||
| US30589801P | 2001-07-18 | 2001-07-18 | |
| US305898P | 2001-07-18 | ||
| PCT/EP2002/005420 WO2002093164A2 (en) | 2001-05-16 | 2002-05-16 | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60212836D1 true DE60212836D1 (de) | 2006-08-10 |
| DE60212836T2 DE60212836T2 (de) | 2007-01-25 |
Family
ID=28043245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60212836T Expired - Lifetime DE60212836T2 (de) | 2001-05-16 | 2002-05-16 | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20030176443A1 (de) |
| EP (2) | EP1721609A3 (de) |
| AT (1) | ATE331519T1 (de) |
| AU (1) | AU2002342878A1 (de) |
| CA (1) | CA2446939C (de) |
| DE (1) | DE60212836T2 (de) |
| WO (1) | WO2002093164A2 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030175926A1 (en) * | 2002-03-05 | 2003-09-18 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| JP2004536097A (ja) * | 2001-06-29 | 2004-12-02 | アブ サイエンス | 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
| EP1401412A2 (de) * | 2001-06-29 | 2004-03-31 | AB Science | Verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von tumorangiogenese |
| ATE343415T1 (de) * | 2001-06-29 | 2006-11-15 | Ab Science | Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen |
| CA2452368A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
| ATE330608T1 (de) * | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
| EP1401413B1 (de) * | 2001-06-29 | 2006-11-22 | AB Science | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen |
| DE60228278D1 (de) * | 2001-09-20 | 2008-09-25 | Ab Science | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung |
| EP1461032B1 (de) * | 2001-09-20 | 2008-07-16 | AB Science | Die verwendung von c-kithemmern zur förderung des haarwuchses |
| ATE334693T1 (de) * | 2002-02-27 | 2006-08-15 | Ab Science | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten |
| WO2004000318A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| US20050260126A1 (en) * | 2002-08-30 | 2005-11-24 | Yukitsuka Kudo | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| AU2003242988A1 (en) * | 2003-06-06 | 2005-01-04 | Adibhatla Kali Sathya Bhujanga Rao | Process for the preparation of the anti-cancer drug imatinib and its analogues |
| MXPA05013349A (es) * | 2003-06-13 | 2006-03-09 | Novartis Ag | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. |
| US8062888B2 (en) | 2004-04-23 | 2011-11-22 | Laura Manuelidis | High throughput assays for transmissible spongiform encephalopathies (TSE) |
| CA2578122A1 (en) * | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| NZ554009A (en) * | 2004-10-18 | 2010-09-30 | Medvet Science Pty Ltd | Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor C-FMS |
| EP1674870B1 (de) * | 2004-11-15 | 2008-06-11 | Roche Diagnostics GmbH | Hoch-Durchsatz Prion Tests |
| ATE445392T1 (de) * | 2005-08-15 | 2009-10-15 | Siegfried Generics Int Ag | Filmtablette oder granulat enthaltend ein pyridylpyrimidin |
| TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| KR20090075889A (ko) * | 2006-11-03 | 2009-07-09 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| MX2009011950A (es) * | 2007-05-04 | 2009-12-11 | Irm Llc | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. |
| BRPI0811516A2 (pt) * | 2007-05-04 | 2014-11-18 | Irm Llc | Compostos e composições como inibidores de c-kit e pdgfr cinase |
| CA2689989A1 (en) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| MX2010002004A (es) | 2007-08-22 | 2010-03-11 | Irm Llc | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa. |
| ES2368876T3 (es) * | 2007-08-22 | 2011-11-23 | Irm Llc | Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa. |
| EP2200436B1 (de) * | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituierte pyrimidinylamine als proteinkinasenhemmer |
| CN101417995B (zh) * | 2008-11-21 | 2012-06-06 | 陈依军 | 苯氧基嘧啶衍生物及其制备方法和用途 |
| JP5959537B2 (ja) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
| CN110078708B (zh) * | 2019-05-08 | 2020-12-11 | 东南大学 | Smo/Bcr-Abl双靶向抑制剂及其合成方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (de) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5612340A (en) * | 1993-10-01 | 1997-03-18 | Ciba-Geigy Corporation | Pyrimidineamine derivatives and processes for the preparation thereof |
| EP0723533A1 (de) * | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | N-alkyl-n-arylpyrimidinamine und ihre derivate |
| TW513418B (en) * | 1996-07-31 | 2002-12-11 | Otsuka Pharma Co Ltd | Thiazole derivatives, their production and use |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| AU747705C (en) * | 1997-12-13 | 2004-09-23 | Bristol-Myers Squibb Company | Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors |
| DE69812177T2 (de) * | 1997-12-31 | 2004-01-15 | Cephalon Inc | 3'-epi k-252a derivate |
| AU765473B2 (en) * | 1999-04-23 | 2003-09-18 | Takeda Pharmaceutical Company Limited | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof |
| MXPA02001108A (es) * | 1999-09-15 | 2002-08-20 | Warner Lambert Co | Pieridinonas como inhibidores de la cinasa. |
-
2002
- 2002-05-16 DE DE60212836T patent/DE60212836T2/de not_active Expired - Lifetime
- 2002-05-16 WO PCT/EP2002/005420 patent/WO2002093164A2/en active IP Right Grant
- 2002-05-16 US US10/204,041 patent/US20030176443A1/en not_active Abandoned
- 2002-05-16 AT AT02769490T patent/ATE331519T1/de not_active IP Right Cessation
- 2002-05-16 AU AU2002342878A patent/AU2002342878A1/en not_active Abandoned
- 2002-05-16 EP EP06013237A patent/EP1721609A3/de not_active Withdrawn
- 2002-05-16 CA CA002446939A patent/CA2446939C/en not_active Expired - Fee Related
- 2002-05-16 EP EP02769490A patent/EP1395261B1/de not_active Expired - Lifetime
-
2006
- 2006-02-08 US US11/350,410 patent/US20060217404A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1395261B1 (de) | 2006-06-28 |
| ATE331519T1 (de) | 2006-07-15 |
| EP1721609A3 (de) | 2007-01-31 |
| US20030176443A1 (en) | 2003-09-18 |
| CA2446939A1 (en) | 2002-11-21 |
| DE60212836T2 (de) | 2007-01-25 |
| AU2002342878A1 (en) | 2002-11-25 |
| WO2002093164A2 (en) | 2002-11-21 |
| WO2002093164A3 (en) | 2003-09-04 |
| EP1395261A2 (de) | 2004-03-10 |
| EP1721609A2 (de) | 2006-11-15 |
| US20060217404A1 (en) | 2006-09-28 |
| CA2446939C (en) | 2005-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60212836D1 (de) | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten | |
| MXPA04012965A (es) | Inhibidores virales. | |
| TR200103336T2 (tr) | Amid türevleri. | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
| DE69615674D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase | |
| NO20053645L (no) | (4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse | |
| DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
| NO20060706L (no) | Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease | |
| CY1110969T1 (el) | 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| NO20080150L (no) | Inhibitorer av AKT-aktivitet | |
| NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
| NO20062101L (no) | Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease | |
| ATE349463T1 (de) | Verbrückte bizyklische serinproteaseinhibitoren | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| NO331068B1 (no) | Benzazepinderivater for behandling av nevrologiske forstyrrelser. | |
| ECSP045378A (es) | Derivados novedosos de diazabiciclononeno | |
| MXPA05010440A (es) | Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b). | |
| ES2243579T3 (es) | Derivados de pirazolopirideno. | |
| EP1817312A4 (de) | Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer | |
| BR9909597A (pt) | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas | |
| BRPI0406646A (pt) | Compostos de(2-carboxamido)(3-amina)tiofenos, bem como composições e usos compreendendo os mesmos | |
| ATE543803T1 (de) | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren | |
| DK1483251T3 (da) | C3-cyano-epothilon-derivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: FOUNDATION FOR FATAL RARE DISEASE, VADUZ, LI |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: ABK PATENTANWAELTE, 82152 PLANEGG |
|
| R082 | Change of representative |
Ref document number: 1395261 Country of ref document: EP Representative=s name: ABK PATENTANWAELTE, 14052 BERLIN, DE |